Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
D.A. Davidson & CO. Grows Stock Holdings in Intellia Therapeutics, Inc. $NTLA
06:16am, Thursday, 30'th Oct 2025
D.A. Davidson and CO. increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 108.0% in the undefined quarter, according to its most recent disclosure with the Securities and Ex
Intellia Therapeutics, Inc. $NTLA Stake Lifted by Cwm LLC
06:16am, Thursday, 30'th Oct 2025
Cwm LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 22.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
US FDA places clinical hold on Intellia's two gene-editing treatment trials
05:11pm, Wednesday, 29'th Oct 2025
Intellia Therapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its two late-stage trials testing an experimental gene-editing therapy for a rare disea
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript
11:17am, Monday, 27'th Oct 2025
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z October 27, 2025 8:30 AM EDT Company Participants Jason Fredette John Leonard
Intellia pauses late-stage trials of gene-editing treatment after serious liver event
07:38am, Monday, 27'th Oct 2025
Intellia Therapeutics said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its one-time gene-editing treatment for a heart condition after a patient exp
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
07:30am, Monday, 27'th Oct 2025
CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
08:15am, Friday, 24'th Oct 2025
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ratin
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
10:25am, Monday, 20'th Oct 2025
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
4 Healthcare Stocks to Buy Now
09:45am, Sunday, 12'th Oct 2025
Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
10:25am, Thursday, 09'th Oct 2025
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 08'th Oct 2025
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know
10:55am, Wednesday, 08'th Oct 2025
The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
10:41am, Wednesday, 08'th Oct 2025
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
1 Stock Up by 63% This Year That Could Double, According to Wall Street
09:45am, Tuesday, 07'th Oct 2025
Shares of Intellia Therapeutics (NTLA -0.29%), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set by W
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd Oct 2025
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
